[November 09, 2012] |
|
Enzo Biochem to Present at Lazard Capital Markets 9th Annual Healthcare Conference
NEW YORK --(Business Wire)--
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and
clinical laboratory company, announced today that Barry Weiner,
President, and David Goldberg, Vice President, Corporate Development,
will be presenting at the Lazard Capital Markets 9th Annual Healthcare
Conference on Tuesday, November 13, 2012 at 9:00 AM at The Pierre
Hotel in New York, N.Y.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and
biotechnology company focused on harnessing biological process to
develop research tools, diagnostics and therapeutics, and serves as a
provider of test services, including exotic tests, to the medical
community. Since our founding in 1976, our strategic focus has been on
the development of enabling technologies in the life sciences field.
Enzo Life Sciences develops, produces and markets proprietary labeling
and detection products for gene sequencing, genetic analysis and
immunological research, among others. Its catalog of over 30,000
products serves the molecular biology, drug discovery and pathology
research markets worldwide. Enzo Clinical Labs provids laboratory
services for a growing roster of physicians in the New York Metropolitan
area, Pennsylvania and New Jersey. Its tests include, in addition to
routine tests, capabilities for detecting molecular infection disease,
molecular oncology, autoimmune disorders and genetics. Enzo Clinical
Labs also provides clinical diagnostic services that allow Enzo to
capitalize on its extensive advanced molecular and cytogenetic
capabilities and the broader trends in predictive and personalized
diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has
developed multiple novel approaches in the areas of gastrointestinal,
infectious, ophthalmic and metabolic diseases. It has focused its
efforts on developing treatment regimens for diseases and conditions for
which current treatment options are ineffective, costly, and/or cause
unwanted side effects. In the course of the company's research and
development activities, Enzo has also developed a substantial portfolio
of intellectual property asset with patent coverage across a number of
key technologies.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management, including those related
to cash flow, gross margins, revenues, and expenses are dependent on a
number of factors outside of the control of the company including, inter
alia, the markets for the Company's products and services, costs of
goods and services, other expenses, government regulations, litigations,
and general business conditions. See Risk Factors in the Company's Form
10-K for the fiscal year ended July 31, 2010. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
[ Back To TMCnet.com's Homepage ]
|